Evotec SE American Depositary Shares (EVO) is a publicly traded Healthcare sector company. As of July 28, 2026, EVO trades at $1.97 with a market cap of $689.06M and a P/E ratio of 0.00. EVO moved +2.76% today. Year to date, EVO is -37.66%; over the trailing twelve months it is -54.93%. Its 52-week range spans $1.91 to $5.10. Analyst consensus is neutral with an average price target of $2.80. Rallies surfaces EVO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Evotec Biologics Introduces J.TRAIN for 500 kg-Scale Continuous Manufacturing in 18 Months: Evotec SE’s Just – Evotec Biologics has launched J.TRAIN, a turnkey continuous manufacturing platform combining modular cleanrooms and cGMP process automation for partner-owned facilities. J.TRAIN can produce over 500 kg of drug substance in under 10 000 sq ft, delivers tenfold higher productivity than fed-batch methods with 18-month deployment timelines.
| Metric | Value |
|---|---|
| Price | $1.97 |
| Market Cap | $689.06M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.07% |
| 52-Week High | $5.10 |
| 52-Week Low | $1.91 |
| Volume | 846 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover EVO: 0 strong buy, 1 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $2.80.